A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors

By Gordon Michael   Ilaria Robert   Alwis Dinesh   Mendelson David   McKane Scott   Wagner Margaret   Look Katherine   LoRusso Patricia  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 21-27

Springer Publishing Company

Access to resources Recommend Favorite

Phase I Trial of Fixed Dose Rate Infusion Gemcitabine with Gefitinib in Patients with Pancreatic Carcinoma

By Carneiro Benedito A.   Brand Randall E.   Fine Elita   Knop Richard H.   Khandekar Janardan D.   Uhlig William   Locker Gershon Y.  

Cancer Investigation, Vol. 25, Iss. 5, 2007-07 ,pp. : 366-371

Informa Healthcare

Access to resources Recommend Favorite

A Phase I Multicenter Study of Continuous Oral Administration of Lonafarnib (SCH 66336) and Intravenous Gemcitabine in Patients With Advanced Cancer

By Wong Nan Soon   Meadows Kellen L.   Rosen Lee S.   Adjei Alex A.   Kaufmann Scott H.   Morse Michael A.   Petros William P.   Zhu Yali   Statkevich Paul   Cutler David L.   Meyers Michael L.   Hurwitz Herbert I.  

Cancer Investigation, Vol. 29, Iss. 9, 2011-10 ,pp. : 617-625

Informa Healthcare

Access to resources Recommend Favorite

Phase I and pharmacokinetic study of 5-fluorouracil administered by 5-day continuous infusion in patients with hepatocellular carcinoma

By Ueno Hideki   Okada Shuichi   Okusaka Takuji   Ikeda Masafumi   Kuriyama Hitoshi  

Cancer Chemotherapy and Pharmacology, Vol. 49, Iss. 2, 2002-02 ,pp. : 155-160

Springer Publishing Company

Access to resources Recommend Favorite

Phase I trial of systemic intravenous infusion of interleukin‐13‐Pseudomonas exotoxin in patients with metastatic adrenocortical carcinoma

By  

Cancer Medicine, Vol. 4, Iss. 7, 2015-07 ,pp. : 1060-1068

John Wiley & Sons Inc

Access to resources Recommend Favorite